Botanix Pharmaceuticals has seen its share price fall to A$0.008 after a prolonged slide, which puts a sharp spotlight on whether the current market value lines up with what the business is generating in sales. With the stock under pressure, the live question is how much revenue support there is for even this lower price.
For investors, the debate is whether Botanix Pharmaceuticals' current share price is adequately supported by the sales the business is producing and that investors expect it to produce in the future.
If you want a reference point while weighing whether Botanix Pharmaceuticals' A$0.008 share price lines up with its sales, compare it with companies in the 3 high quality undervalued stocks.
The P/S ratio fits Botanix Pharmaceuticals because revenue is the key reference point when earnings are not a reliable guide. On this measure, the stock trades on a P/S of 0.7x, which sits well below the broader Pharmaceuticals sector average of 5.2x and the peer group closer to 8.0x. That is a wide gap for a business that the market is still valuing at A$0.008 per share.
The valuation model suggests a higher P/S would be typical for Botanix Pharmaceuticals once its growth profile, margins, size and risk factors are all taken into account. As a result, the current 0.7x reads as discounted against that tailored yardstick. For anyone weighing the shares, the question is whether the revenue base and pipeline potential eventually justify a multiple closer to that implied level, or whether the present low P/S is a fair reflection of execution and funding risks. Explore the numbers behind Botanix Pharmaceuticals's P/S valuation.
Simply Wall St Narratives for Botanix Pharmaceuticals pick up where the P/S puzzle leaves off and explain what kind of future growth, profitability and earnings profile would need to occur for the current A$0.008 share price to appear either too low or too high. They use the Community page as a place to set out those scenarios in a structured way. Each narrative links its valuation view to a specific path for Botanix Pharmaceuticals' growth, margins and risk profile that you can revisit as new results or clinical updates are released.
One of the top narratives on Botanix Pharmaceuticals: 20% undervalued
This Narrative is the bearish analyst Narrative on Simply Wall St, built on the most pessimistic analyst price target and forecasts, not one person's view.
"The current numbers around Sofdra prescription volumes, refill rates, cost reductions, and cash-flow targets imply that the share price reflects limited value..."
Discover why this Narrative puts Botanix Pharmaceuticals at 20% undervalued.
Price to sales tells you where Botanix Pharmaceuticals trades today, but analyst projections a few years out show what expectations are already baked into that figure. Explore where analysts expect Botanix Pharmaceuticals to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com